Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study
- 30 August 2012
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 135 (3), 821-830
- https://doi.org/10.1007/s10549-012-2223-1
Abstract
Metformin may exert anti-cancer effects through indirect (insulin-mediated) or direct (insulin-independent) mechanisms. We report results of a neoadjuvant “window of opportunity” study of metformin in women with operable breast cancer. Newly diagnosed, untreated, non-diabetic breast cancer patients received metformin 500 mg tid after diagnostic core biopsy until definitive surgery. Clinical (weight, symptoms, and quality of life) and blood [fasting serum insulin, glucose, homeostasis model assessment (HOMA), C-reactive protein (CRP), and leptin] attributes were compared pre- and post-metformin as were terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and Ki67 scores (our primary endpoint) in tumor tissue. Thirty-nine patients completed the study. Mean age was 51 years, and metformin was administered for a median of 18 days (range 13–40) up to the evening prior to surgery. 51 % had T1 cancers, 38 % had positive nodes, 85 % had ER and/or PgR positive tumors, and 13 % had HER2 overexpressing or amplified tumors. Mild, self-limiting nausea, diarrhea, anorexia, and abdominal bloating were present in 50, 50, 41, and 32 % of patients, respectively, but no significant decreases were seen on the EORTC30-QLQ function scales. Body mass index (BMI) (−0.5 kg/m2, p < 0.0001), weight (−1.2 kg, p < 0.0001), and HOMA (−0.21, p = 0.047) decreased significantly while non-significant decreases were seen in insulin (−4.7 pmol/L, p = 0.07), leptin (−1.3 ng/mL, p = 0.15) and CRP (−0.2 mg/L, p = 0.35). Ki67 staining in invasive tumor tissue decreased (from 36.5 to 33.5 %, p = 0.016) and TUNEL staining increased (from 0.56 to 1.05, p = 0.004). Short-term preoperative metformin was well tolerated and resulted in clinical and cellular changes consistent with beneficial anti-cancer effects; evaluation of the clinical relevance of these findings in adequately powered clinical trials using clinical endpoints such as survival is needed.Keywords
This publication has 34 references indexed in Scilit:
- Diabetes, Metformin, and Breast Cancer in Postmenopausal WomenJournal of Clinical Oncology, 2012
- Metformin and breast cancer risk: a meta-analysis and critical literature reviewBreast Cancer Research and Treatment, 2012
- Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 DiabetesDiabetes Care, 2011
- Associations of Insulin Resistance and Adiponectin With Mortality in Women With Breast CancerJournal of Clinical Oncology, 2011
- Clinically Defined Type 2 Diabetes Mellitus and Prognosis in Early-Stage Breast CancerJournal of Clinical Oncology, 2011
- Fasting C-Peptide Levels and Death Resulting From All Causes and Breast Cancer: The Health, Eating, Activity, and Lifestyle StudyJournal of Clinical Oncology, 2011
- Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysisCancer Prevention Research, 2010
- Metabolic profile, physical activity, and mortality in breast cancer patientsBreast Cancer Research and Treatment, 2009
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast CancerJournal of Clinical Oncology, 2009
- Insulin-Lowering Effects of Metformin in Women with Early Breast CancerClinical Breast Cancer, 2008